Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: Chugai's optic disease drug meets primary endpoint

(CercleFinance.com) - Roche's Japanese subsidiary Chugai said its treatment for neuromyelitis optica spectrum disorder, a rare relapsing autoimmune disease that causes inflammation in the optic nerve, has met its primary endpoint in a late-stage trial.


A phase III study on Satralizumab has achieved its primary endpoint, which was defined as the time to first relapse.

In a statement, Roche said that a "statistically significant reduction" in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo.

Copyright (c) 2018 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.